<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00085111</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-01813</org_study_id>
    <secondary_id>ADVL0314</secondary_id>
    <secondary_id>COG-ADVL0314</secondary_id>
    <secondary_id>CDR0000367299</secondary_id>
    <secondary_id>NCI-04-C-0148</secondary_id>
    <secondary_id>U01CA097452</secondary_id>
    <nct_id>NCT00085111</nct_id>
    <nct_alias>NCT00080561</nct_alias>
  </id_info>
  <brief_title>Bevacizumab in Treating Young Patients With Refractory Solid Tumors</brief_title>
  <official_title>A Phase I Study of Bevacizumab in Refractory Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase I trial is studying the side effects and best dose of bevacizumab in treating&#xD;
      young patients with refractory solid tumors. Monoclonal antibodies, such as bevacizumab, can&#xD;
      locate tumor cells and either kill them or deliver tumor-killing substances to them without&#xD;
      harming normal cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To estimate the maximum tolerable dose (MTD) of bevacizumab by dose escalation to a&#xD;
      maximum of 15mg/kg, even if MTD is not reached, administered as an intravenous infusion,&#xD;
      every 2 weeks to children with refractory solid tumors.&#xD;
&#xD;
      II. To determine the dose-limiting toxicities (DLT) and other toxicities of bevacizumab given&#xD;
      on this schedule.&#xD;
&#xD;
      III. To characterize the pharmacokinetic behavior of bevacizumab in children with refractory&#xD;
      cancer.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To preliminarily define the antitumor activity of bevacizumab within the confines of a&#xD;
      phase I study.&#xD;
&#xD;
      II. To assess the biologic activity of bevacizumab by measuring levels of total serum VEGF,&#xD;
      and parallel angiogenic markers V-CAM-1, ICAM-1, bFGF, and TSP-1 at baseline and at time&#xD;
      points post therapy.&#xD;
&#xD;
      III. To explore the biologic effect of bevacizumab on circulating endothelial cells (CECs)&#xD;
      and circulating endothelial cell precursors (CECPs).&#xD;
&#xD;
      IV. To determine in archival tumor tissue the expression of VEGF by immunohistochemistry&#xD;
      and/or real time PCR.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation, multicenter study.&#xD;
&#xD;
      Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every&#xD;
      28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of bevacizumab until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2&#xD;
      of 6 patients experience dose-limiting toxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2003</start_date>
  <primary_completion_date type="Actual">October 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose defined based on the dose-limiting toxicities graded according to Common Terminology Criteria for Adverse Events v3.0</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Unspecified Childhood Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>anti-VEGF humanized monoclonal antibody</other_name>
    <other_name>anti-VEGF monoclonal antibody</other_name>
    <other_name>Avastin</other_name>
    <other_name>rhuMAb VEGF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed solid tumor at original diagnosis&#xD;
&#xD;
          -  Measurable or evaluable* disease&#xD;
&#xD;
          -  No known curative therapy exists&#xD;
&#xD;
          -  No lymphomas or primary CNS tumors&#xD;
&#xD;
          -  No history or clinical evidence of CNS metastasis by head CT scan&#xD;
&#xD;
          -  Performance status - Karnofsky 50-100% (patients &gt; 10 years of age)&#xD;
&#xD;
          -  Performance status - Lansky 50-100% (patients ≤ 10 years of age)&#xD;
&#xD;
          -  At least 8 weeks&#xD;
&#xD;
          -  Patients without bone marrow involvement:&#xD;
&#xD;
               -  Absolute neutrophil count ≥ 1,000/mm^3&#xD;
&#xD;
               -  Platelet count ≥ 100,000/mm^3 (transfusion independent)&#xD;
&#xD;
               -  Hemoglobin ≥ 8.0 g/dL (RBC transfusion allowed)&#xD;
&#xD;
          -  Patients with bone marrow metastases:&#xD;
&#xD;
               -  Platelet count ≥ 75,000/mm^3 (transfusion independent)&#xD;
&#xD;
               -  Granulocytopenia, anemia, and/or mild thrombocytopenia allowed&#xD;
&#xD;
          -  No known bleeding diathesis or coagulopathy&#xD;
&#xD;
          -  No known thrombophilic condition (e.g., protein S, protein C, or antithrombin III&#xD;
             deficiency, Factor V Leiden, Factor II G20210A mutation, homocystinemia, or&#xD;
             antiphospholipid antibody syndrome)&#xD;
&#xD;
          -  PT or PTT ≤ 1.2 times upper limit of normal (ULN)&#xD;
&#xD;
          -  ALT ≤ 5 times ULN&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times ULN&#xD;
&#xD;
          -  Albumin ≥ 2 g/dL&#xD;
&#xD;
          -  Creatinine clearance or radioisotope glomerular filtrationrate ≥ 70 mL/min&#xD;
&#xD;
          -  Creatinine based on age as follows:&#xD;
&#xD;
               -  Creatinine ≤ 0.8 mg/dL (patients ≤ 5 years of age)&#xD;
&#xD;
               -  Creatinine ≤ 1.0 mg/dL (patients 6 to 10 years of age)&#xD;
&#xD;
               -  Creatinine ≤ 1.2 mg/dL (patients 11 to 15 years of age)&#xD;
&#xD;
               -  Creatinine ≤ 1.5 mg/dL (patients &gt; 15 years of age)&#xD;
&#xD;
          -  No proteinuria&#xD;
&#xD;
          -  24-hour urine protein ≤ 500 mg&#xD;
&#xD;
          -  No history of stroke&#xD;
&#xD;
          -  No deep venous or arterial thrombosis within the past 3 months&#xD;
&#xD;
          -  No uncontrolled hypertension&#xD;
&#xD;
               -  Hypertension must be well-controlled with stable doses of medication for at least&#xD;
                  2 weeks&#xD;
&#xD;
          -  No history of myocardial infarction&#xD;
&#xD;
          -  No severe or unstable angina&#xD;
&#xD;
          -  No transient ischemic attack within the past 6 months&#xD;
&#xD;
          -  No cerebrovascular accident within the past 6 months&#xD;
&#xD;
          -  No other arterial thromboembolic event within the past 6 months&#xD;
&#xD;
          -  No clinically significant or severe peripheral vascular disease&#xD;
&#xD;
          -  No pulmonary embolism within the past 3 months&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for at least 3 months&#xD;
             after study participation&#xD;
&#xD;
          -  No chronic non-healing wound, ulcer, or bone fracture&#xD;
&#xD;
          -  No significant traumatic injury within the past 28 days&#xD;
&#xD;
          -  No uncontrolled seizures&#xD;
&#xD;
          -  No uncontrolled infection&#xD;
&#xD;
          -  No known hypersensitivity to Chinese hamster ovary cell products or other recombinant&#xD;
             human antibodies&#xD;
&#xD;
          -  Recovered from prior immunotherapy&#xD;
&#xD;
          -  More than 1 week since prior growth factors&#xD;
&#xD;
          -  At least 2 months since prior stem cell transplantation&#xD;
&#xD;
               -  No evidence of active graft-vs-host disease&#xD;
&#xD;
          -  At least 8 weeks since prior monoclonal antibody therapy&#xD;
&#xD;
          -  At least 7 days since prior antineoplastic biologic agents&#xD;
&#xD;
          -  No prior bevacizumab&#xD;
&#xD;
          -  No concurrent prophylactic growth factors&#xD;
&#xD;
          -  No other concurrent immunotherapy or biologic therapy&#xD;
&#xD;
          -  More than 3 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosoureas)&#xD;
             and recovered&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
          -  Recovered from prior radiotherapy&#xD;
&#xD;
          -  At least 4 months since prior craniospinal radiotherapy&#xD;
&#xD;
          -  At least 4 months since prior radiotherapy to ≥ 50% of the pelvis&#xD;
&#xD;
          -  At least 6 weeks since other prior substantial bone marrow radiotherapy&#xD;
&#xD;
          -  At least 2 weeks since prior local palliative small-port radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
          -  More than 28 days since prior major surgery&#xD;
&#xD;
          -  At least 7 days since prior minor surgery (for limited purposes of tissue retrieval)&#xD;
             and recovered&#xD;
&#xD;
          -  At least 24 hours since prior placement of an indwelling IV catheter&#xD;
&#xD;
          -  At least 1 week since prior full-dose anticoagulation therapy, including systemic&#xD;
             thrombolytic agents, heparin, low-molecular weight heparin, and warfarin&#xD;
&#xD;
               -  Local intralumenal anticoagulants (e.g., heparin or tissue plasminogen activator)&#xD;
                  allowed to maintain patency of preexisting, permanent, indwelling IV catheters or&#xD;
                  peripheral IV catheters for blood sampling&#xD;
&#xD;
          -  More than 1 week since prior antipyretic and anti-inflammatory medications (except&#xD;
             acetaminophen)&#xD;
&#xD;
          -  No concurrent full-dose anticoagulation therapy&#xD;
&#xD;
          -  No concurrent anti-inflammatory medication&#xD;
&#xD;
          -  Concurrent acetaminophen allowed&#xD;
&#xD;
          -  No other concurrent cancer therapy&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julia Bender</last_name>
    <role>Principal Investigator</role>
    <affiliation>COG Phase I Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>COG Phase I Consortium</name>
      <address>
        <city>Arcadia</city>
        <state>California</state>
        <zip>91006-3776</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>June 10, 2004</study_first_submitted>
  <study_first_submitted_qc>June 10, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2004</study_first_posted>
  <last_update_submitted>June 4, 2013</last_update_submitted>
  <last_update_submitted_qc>June 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Antineoplastic Agents, Immunological</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

